Nothing we don’t know or expect given the access to data room Amicus would have had for many months - patient level data from phase 2? They are simply stating what we already expect revenues of $100Mn’s just after approval and reach a $Bn revenues in coming years/ peak. That’s the kind of games US biotechs play and they are easily justifying throwing $30Mn to back their conviction and market opportunity. Is that what we are all doing today betting on a $300Mn MC company with 10X in 2-3 years? AIMO.
DXB Price at posting:
51.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)